and good morning or good afternoon, everyone. I'll now take you through our recent business updates. ? As a reminder, slide 12 outlines our multi-year revenue growth strategy, which continues to be anchored in two key drivers: geographic expansion and portfolio expansion through continued pipeline advancement. ? We are building a more diversified portfolio with new opportunities across respiratory vaccines, oncology, and rare diseases, while expanding our commercial footprint in markets around the ? world. We're making tangible progress against this strategy with several important milestones achieved during the quarter. Starting with M Flusiva, we recently received FDA approval for adults aged 50 to 64 and accelerated approval for adults aged 65 65 and older in the U.S. In Canada, we secured approvals for both MFUSIVA and MCOFU, the local brand name for Encombriax for adults aged 60 and older. ? For M Next Spike, we saw approvals for the annual strain updates in the United States, Canada, Japan, and Taiwan for the 2026 2027 vaccination season. ? And for MRESVIA, we continue to make progress in the U.S. and international markets. We expanded our international presence with a five-year agreement signed with a local manufacturer in Mexico to support COVID-19 vaccine supply. And finally, in oncology, we presented positive phase three data for antismerin in adjuvant melanoma at the ESMO Presidential Symposium as highlighted earlier. These milestones demonstrate continued execution against our strategy to drive revenue growth. Turning to our approved infectious disease portfolio, we continue to make progress across our five commercial products. Starting with our COVID vaccines. ? As I mentioned earlier, M Next Spike received approval for the updated XFG strain for this coming vaccination season in the United States, Canada, Japan, and Taiwan, with additional regulatory reviews and filings underway. Spike Fax has also received approval for the updated strain in these markets and also in the European Union. Deliveries of our updated COVID 19 vaccines are now underway globally. Turning to RSV, MRESVIA is approved in 44 countries. We also received published results from a phase 3 study evaluating revaccination with MRESVIA in adults age 60 and older who had previously received a protein based RSV vaccine. The study demonstrated robust immune responses comparable to those seen following the initial vaccination with MRESVIA, with no new safety concerns identified, highlighting the potential ? for MRESVIA in revaccination. ? A link to the study can be found on this ? slide. For M Flusiva, our seasonal influenza vaccine, we have approvals in the United States and now Canada, with reviews ongoing in the European Union, Australia, and Taiwan. In the US, the American Academy of Family Physicians has recommended M Flusiva for adults age 65 and older as an enhanced influenza vaccine. And finally, for M.Combriax, our combination influenza and COVID 19 vaccine, we now have approvals in Europe and Canada. The product remains under review in Japan, the United Kingdom, Australia, and Switzerland, with a decision on filing in the United States subject to further discussion with EFDA. Turning to U.S. respiratory vaccination trends, overall demand remains strong, as was said before. Through late October, approximately 44.1 million flu, COVID-19, and RSV vaccinations have been administered in the retail and long-term care channels, a 3% increase over the comparable period last ? year. Flu vaccinations are trending slightly ahead of last year, and COVID-19 vaccinations are trending slightly behind, but momentum in October suggests vaccinations may end up flat year over year in the channel. These trends demonstrate the healthy demand for seasonal respiratory vaccines in the United States. Turning to our late-stage infectious disease pipeline and our norovirus vaccine program, mRNA 1403. ? As a reminder, as previously disclosed, the phase three study did not meet the statistical criteria for early success at its interim analysis. Following a review of the program, we have decided not to enroll an additional cohort this coming winter season. Instead, we are engaging with health authorities to determine the next steps for the programs. The program and we'll provide further updates following those discussions. With that, I'll I'll now turn the call over to David to review our oncology and rare disease pipeline.
Passages & reports (33) 11:42 and good morning or good afternoon, everyone. I'll now take you through our recent busines… Report 11:47 As Report 11:47 a reminder, slide 12 outlines our multi-year revenue growth strategy, which continues to b… Report 12:01 We Report 12:01 are building a more diversified portfolio with new opportunities across respiratory vaccin… Report 12:13 world. Report 12:14 We're making tangible progress against this strategy with several important milestones ach… Report 12:33 secured approvals for both MFUSIVA and MCOFU, the local brand name for Encombriax for adul… Report 12:42 For Report 12:43 M Next Spike, we saw approvals for the annual strain updates in the United States, Canada,… Report 12:53 And Report 12:53 for MRESVIA, we continue to make progress in the U.S. and international markets. We expand… Report 13:12 melanoma at the ESMO Presidential Symposium as highlighted earlier. These milestones demon… Report 13:32 vaccines. Report 13:33 As Report 13:33 I mentioned earlier, M Next Spike received approval for the updated XFG strain for this co… Report 13:53 markets and also in the European Union. Deliveries of our updated COVID 19 vaccines are no… Report 14:13 older who had previously received a protein based RSV vaccine. The study demonstrated robu… Report 14:27 for Report 14:27 MRESVIA in revaccination. Report 14:30 A Report 14:30 link to the study can be found on this Report 14:32 slide. For Report 14:33 M Flusiva, our seasonal influenza vaccine, we have approvals in the United States and now … Report 14:53 influenza vaccine. And finally, for M.Combriax, our combination influenza and COVID 19 vac… Report 15:12 EFDA. Turning to U.S. respiratory vaccination trends, overall demand remains strong, as wa… Report 15:32 a 3% increase over the comparable period last Report 15:36 year. Report 15:37 Flu vaccinations are trending slightly ahead of last year, and COVID-19 vaccinations are t… Report 15:57 Turning to our late-stage infectious disease pipeline and our norovirus vaccine program, m… Report 16:04 As Report 16:04 a reminder, as previously disclosed, the phase three study did not meet the statistical cr… Report 16:23 programs. The program and we'll provide further updates following those discussions. With … Report